Market attractiveness remains robust, driven by expanding minimally invasive surgery volumes and rising demand for rapid hemostasis across orthopedics, cardiovascular and wound‑closure applications. Competitive intensity is moderate; a handful of global players such as Ethicon, Medtronic and B. Braun dominate, while niche innovators pursue specialty formulations, creating a balanced rivalry that encourages price stability. The long‑term outlook is positive, with CAGR projected above 7% through 2035 as aging populations and outpatient procedures fuel sustained growth. Innovation landscape is vibrant, with advances in bio‑compatible monomers, controlled‑release additives and hybrid sealants that broaden clinical indications. Demand–supply balance is currently tight; supply chains are adapting to higher raw‑material costs, yet manufacturers are scaling capacity to meet rising orders. Key risk factors include regulatory delays for new chemistries, potential adverse‑event litigation and raw‑material price volatility. Overall, the Cyanoacrylate Surgical Sealant and Adhesive market outlook suggests a lucrative, yet carefully managed, opportunity for firms that can align R&D with evolving clinical needs.